Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS

Published:2016-07-19 Issue:9 Volume:139 Page:2127-2134
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Guerrieri-Gonzaga Aliana¹,Sestak Ivana²,Lazzeroni Matteo¹,Serrano Davide¹,Rotmensz Nicole³,Cazzaniga Massimiliano¹,Varricchio Clara¹,Pruneri Giancarlo⁴⁵,Leonardi Maria Cristina⁶,Orecchia Roberto⁵⁶,Galimberti Viviana⁷,Bonanni Bernardo¹,DeCensi Andrea¹²⁸

Affiliation:

1. Divisions of Cancer Prevention and Genetics; European Institute of Oncology Milan; Italy

2. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London; United Kingdom

3. Epidemiology and Biostatistics; European Institute of Oncology Milan; Italy

4. Pathology; European Institute of Oncology Milan; Italy

5. University of Milan, School of Medicine; Milan Italy

6. Radiotherapy; European Institute of Oncology Milan; Italy

7. Breast Surgery; European Institute of Oncology Milan; Italy

8. Division of Medical Oncology; E.O. Ospedali Galliera; Genoa Italy

Funder

Lega Italiana per la Lotta contro i Tumori

Gruppo Bancario Credito Valtellinese

Ministero della Salute

Cancer Research UK

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference45 articles.

1. Selecting individualized treatment for patients with ductal carcinoma in situ of the breast: the search continues;Solin;J Clin Oncol,2012

2. National Institutes of Health State-of-the-Science Conference statement: diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009;Allegra;J Natl Cancer Inst,2010

3. Recent advances and current controversies in the management of DCIS of the breast;Sakorafas;Cancer Treat Rev,2008

4. Addressing overtreatment of screen detected DCIS; the LORIS trial;Francis;Eur J Cancer,2015

5. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ;Worni;J Natl Cancer Inst,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Articles From 2023: Informing Practice Across the Continuum of Care;Annals of Surgical Oncology;2024-05-11

2. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?;Drugs;2024-03-14

3. Current status and challenges of breast cancer prevention~DNA methylation would lead to groundbreaking progress in breast cancer prevention~;Genes and Environment;2023-12-12

4. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial);BMC Cancer;2023-09-14

5. Radiation Management of DCIS and Elimination of RT in Low-risk Disease;Current Breast Cancer Reports;2023-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3